Market Trends of Huntington's Disease Treatment Industry
The Symptomatic Treatment Segment is Expected to Hold a Major Market Share During the Forecast Period
Symptomatic treatment of Huntington’s disease majorly focuses on motor impairment and chorea. Chorea remains the most prominent clinical feature of Huntington's disease, for which most therapeutic studies have been conducted. Relatively high availability and usage rates of symptom management therapeutics are expected to account for a significant share during the forecast period.
The rising need for multiple treatments and the intervention of a multispecialty care team for symptomatic management resulting in additional expenses may contribute to the development of the segment during the forecast period.
Key factors such as rising awareness campaigns and increasing product developments by various market players are expected to contribute to the growth of the segment. For instance, in May 2023, Neurocrine Biosciences Inc. reported complete findings from the Phase 3 KINECT-HD study investigating Valbenazine for treating Huntington's disease (HD) chorea. According to the company, Valbenazine showed a statistically significant improvement over the placebo in the Total Maximal Chorea (TMC) score.
In September 2022, Teva Pharmaceutical launched the Honestly HD website to help people better understand what to expect from Huntington's disease (HD) chorea, one of HD's most apparent and curable symptoms, and how to communicate to their doctor about maintaining independence.
Also, the surge in emphasis on symptomatic treatment of disease is further expected to accelerate segment expansion during the forecast period. For instance, according to an article published by Neurological Research and Practice in November 2023, treatment approaches such as pharmacotherapy and behavioral treatments should be individually adapted to manage several signs and symptoms of Huntington’s disease, including myoclonus, dystonia, and chorea. Thus, such increased emphasis on symptomatic treatment of disease is likely to augment segment expansion during the forecast period.
Therefore, key players' continuous R&D activities and awareness programs are expected to create lucrative opportunities for the segment during the forecast period.
North America is Expected to Hold a Significant Market Share During the Forecast Period
North America is expected to hold a significant market share during the forecast period due to the rising incidence of Huntington's disease, the presence of key players, and growing R&D funding by the government and private organizations. According to the April 2024 updated data of McGill University, Huntington’s disease has emerged as a significant disease in Canada, and it affects around 1 in 7,000 people in Canada. As Huntington's condition becomes more prevalent in this region, demand for efficient treatments is anticipated to rise, driving the growth of the target market throughout the forecast period.
Companies ' increasing product development and R&D activities are expected to fuel the market's growth during the forecast period. For instance, in June 2024, PTC Therapeutics Inc. published the Phase II interim results from the PIVOT-HD study of PTC518 in Huntington's disease (HD) patients. The results showed a significant decrease in mutant huntingtin (mHTT) protein in the blood. Thus, such increased product development activities and R&D activities by the market participants are likely to foster the development of new therapeutics, which is expected to boost market growth during the forecast period.
Moreover, the growing funding activities for Huntington’s disease research in the United States are further anticipated to accelerate market growth. For instance, according to 2024 updated data from the National Institute of Health, the estimated funding for Huntington’s disease research ramped from 49 million in 2024 to 50 million in 2025. Thus, the growing research funding for Huntington’s disease will likely accelerate the development of novel therapeutics, which, in turn, is projected to boost market growth during the forecast period.
Also, the growing regulatory approvals of novel therapeutics are further expected to propel the commercialization of innovative treatment options, further boosting market growth during the forecast period. For instance, in August 2023, the US Food and Drug Administration approved Neurocrine Biosciences Inc.’s INGREZZA (valbenazine) capsules for the management of chorea associated with Huntington's disease. Such approvals are anticipated to propel regional market growth during the forecast period.
As a result, the rising prevalence of the target disease, increased R&D, and supportive regulatory authorities are anticipated to contribute to the market expansion in this region during the forecast period.
